Researchers and a patient advocate weighed in on current and emerging treatment options for each stage of triple-negative breast...
Guest post by Michele R. McCorkle, RN, MSN Executive Director, Oncology Nursing Society
A half marathon is a challenging goal for anyone. Several members of the American Association for Cancer Research (AACR)...
Yesterday, Onivyde, which is a nanotherapeutic form of the conventional chemotherapeutic irinotecan, was approved by the U.S. Food and...
Jamie Holloway, a breast cancer researcher turned breast cancer patient and AACR Scientist↔Survivor Program advocate, started a blog to...
The American Association for Cancer Research held two community events this week aimed at engaging the public in the...
Guest Post by Roswell Park Cancer Institute Department of Public Affairs
An emerging hallmark of cancer cells is their ability to hide from the body’s immune system. The human immune...
Late last week, the U.S. Food and Drug Administration (FDA) announced that it had approved the use of the...
Guest Post by William G. Nelson, MD, PhD Editor-in-Chief, Cancer Today
The number of anticancer immunotherapeutics approved by the U.S. Food and Drug Administration (FDA) is rising rapidly. In fact,...